Cerus Q2 revenue beats estimates, raises 2025 guidance

Cerus

05/08/2025 21:09

Overview

Cerus Q2 total revenue rises 19% yr/yr to $60.1 mln, beating estimates, per LSEG data

Q2 product revenue up 16% yr/yr to $52.4 mln, driven by IFC and platelet sales

Co raises full-year 2025 product revenue guidance to $200 mln - $203 mln

Outlook

Cerus raises full-year 2025 product revenue guidance to $200 mln-$203 mln

Company increases 2025 IFC revenue guidance to $16 mln-$18 mln

Cerus expects positive full-year 2025 non-GAAP adjusted EBITDA

Company anticipates continued growth in second half of 2025

Result Drivers

IFC DEMAND - Strong demand for INTERCEPT Fibrinogen Complex drove product revenue growth, with Q2 revenue rising to $5.6 mln from $2.0 mln year-ago

INT200 DEVICE - Successful launch and adoption of the new LED-based INT200 illumination device exceeded performance expectations, per CEO

GOVERNMENT CONTRACTS - Increase in government contract revenue was driven by R&D activities for the INTERCEPT RBC program and next-gen pathogen reduction technology

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$60.10 mln
$54.40 mln (4 Analysts)
Q2 Net Income
-$5.70 mln
Q2 Adjusted EBITDA
Miss
$900,000
$2.12 mln (3 Analysts)
Q2 Gross Margin
55.2%
Q2 Gross Profit
$29 mln
Q2 Operating Expenses
$40.10 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Cerus Corp is $5.00, about 74% above its August 4 closing price of $1.30

Press Release: ID:nBw4Q9ct8a

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)